Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials

Clinical Drug Investigation

Volumn 36, Issue 11, 2016, Pages 865-875

  Wang, Li ^a   Zhai, Chun juan ^a   Liu, Yao ^a   Liu, Yi ^a   Jiang, Shu juan ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SALBUTAMOL; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; QUINUCLIDINE DERIVATIVE;

BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; LUNG FUNCTION; META ANALYSIS; MONOTHERAPY; OROPHARYNX PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; DRUG EFFECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALBUTEROL; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84982308364     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0449-0     Document Type: Review

References (23)

1. Global initiative for chronic obstructive lung disease (GOLD 2016). www.goldcopd.org. Accessed 3 May 2016.
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
4. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–67.
5. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–8.
6. de Miguel-Diez J, Jimenez-Garcia R. Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014;23(4):453–6.
7. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg C, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–91.
8. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–86.
9. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Rev Esp Salud Publica. 2000;74(2):107–18.
10. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions. Version 5.0.2. 2009. New York: Wiley. The Cochrane Cllaboration. http://www.cochrane-handbook.org. Accessed June 2008.
11. Laurendeau C, Pribil C, Perez T, Roche N, Simeoni MC, Detournay B. Validation study of the BDI/TDI scores in chronic obstructive pulmonary disease. Rev Mal Respir. 2009;26(7):735–43.
12. Wilcox TK, Chen WH, Howard KA, Wiklund I, Brooks J, Watkins ML, et al. Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:196.
13. Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 1999;54(11):995–1003.
14. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465–71.
15. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–46.
16. Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
17. Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169–81.
18. Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148(2):397–407.
19. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25.
20. 2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104.
21. Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med. 2014;8(3):357–79.
22. Miravitlles M, Galdiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F. Cost-effectiveness of umeclidinium/vilanterol in symptomatic COPD Spanish patients. Value Health. 2015;18(7):A500–1.
23. Punekar YS, Roberts G, Ismaila A, O’Leary M. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. Cost Eff Resour Alloc. 2015;13:22.